NYSE:BMY Bristol Myers Squibb Q3 2025 Earnings Report $43.83 -0.56 (-1.27%) As of 01:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Bristol Myers Squibb EPS ResultsActual EPSN/AConsensus EPS $1.65Beat/MissN/AOne Year Ago EPSN/ABristol Myers Squibb Revenue ResultsActual RevenueN/AExpected Revenue$11.75 billionBeat/MissN/AYoY Revenue GrowthN/ABristol Myers Squibb Announcement DetailsQuarterQ3 2025Date10/30/2025TimeBefore Market OpensConference Call DateThursday, October 30, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Bristol Myers Squibb Earnings HeadlinesAnalyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy2 hours ago | finance.yahoo.comAnalyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy2 hours ago | insidermonkey.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 23 at 2:00 AM | Brownstone Research (Ad)Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should KnowOctober 21 at 11:04 PM | msn.comTruist Financial Remains a Buy on Bristol-Myers Squibb (BMY)October 21 at 1:01 PM | theglobeandmail.comThe Play On Bristol-Myers SquibbOctober 21 at 11:30 AM | seekingalpha.comSee More Bristol Myers Squibb Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bristol Myers Squibb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bristol Myers Squibb and other key companies, straight to your email. Email Address About Bristol Myers SquibbBristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines for patients with serious diseases. The company’s research and development efforts are primarily focused on oncology, immunology, cardiovascular disease and fibrosis. Through a combination of internal research programs and strategic acquisitions, Bristol Myers Squibb aims to address critical unmet medical needs and improve long-term health outcomes. The company’s portfolio includes a range of marketed therapies such as Opdivo for multiple cancers, Eliquis for stroke prevention in atrial fibrillation and various immunology treatments. Following its acquisition of Celgene, Bristol Myers Squibb also integrated several hematology and oncology products, further strengthening its position in specialized medicine. Its pipeline features both small molecules and biologics, with ongoing clinical trials exploring novel mechanisms of action across a spectrum of disease areas. Founded in 1989 through the merger of Bristol-Myers Company and Squibb Corporation—and tracing its roots back to the mid-19th century—Bristol Myers Squibb is headquartered in New York and operates in more than 60 countries worldwide. The company maintains research facilities in North America, Europe and Asia, and collaborates with academic institutions, biotechnology firms and other pharmaceutical companies to advance scientific innovation. Under the leadership of Chief Executive Officer Giovanni Caforio, Bristol Myers Squibb continues to pursue a patient-centric strategy aimed at delivering transformative therapies on a global scale.View Bristol Myers Squibb ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla’s Earnings Review: Does the Juice Justify the Squeeze?Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings Signal Upcoming Earnings Sanofi (10/24/2025)ENI (10/24/2025)General Dynamics (10/24/2025)HCA Healthcare (10/24/2025)ICICI Bank (10/24/2025)Illinois Tool Works (10/24/2025)Coca Cola Femsa (10/24/2025)NatWest Group (10/24/2025)Procter & Gamble (10/24/2025)Cadence Design Systems (10/27/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.